Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart-Safe anesthesia: drug may tame dangerous racing pulse

NCT ID NCT01259648

Symptom relief Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding remifentanil, a fast-acting painkiller, to standard emergency anesthesia could prevent a dangerously fast heart rate in fragile patients. 75 adults needing rapid-sequence intubation received either a low or high dose of remifentanil or a placebo. The goal was to see if it safely controls heart rate during the procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
remifentanil
What this could lead to
If it works, this could provide a safer way to manage heart rate during emergency anesthesia in fragile patients.
What could go wrong
This is a small, completed Phase 4 trial with only 75 participants, so results may not apply broadly. The drug may not significantly reduce tachycardia or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

75 people

The number who actually took part.

Started

Mar 2011

Finished

May 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients requiring rapid sequence intubation for whatever reason. This includes the following: a full stomach, obesity, diabetic gastroparesis, gastroesophageal reflux * Patient able to give informed consent, and sign the consent. Exclusion Criteria: * Contraindication for the use of any drugs used (regardless of the patient group): a history of serious side effects, allergic reaction * Morbid obesity (Body Mass Index \> 40) * Emergency situation with unstable hemodynamics, and stabilization is impossible before induction * Inclusion in another research project within the past 3 months * The patient is not insured or beneficiary of a health insurance plan (for the French centers) * Patient under guardianship of any kind * Patient unable to give informed consent * Refusal to sign the consent form

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tachycardia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tachycardia

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de Nîmes

    Nîmes, Gard, 30029, France

  • Polyclinique Grand Sud

    Nîmes, Gard, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.